Sergio Traversa, Relmada Therapeutics CEO

Rel­ma­da makes 'crit­i­cal changes' to PhI­II tri­al to try and save de­pres­sion drug

Rel­ma­da Ther­a­peu­tics is mak­ing changes to its Phase III study of its lead drug for ma­jor de­pres­sive dis­or­der, in an at­tempt to avoid prob­lems with a pri­or tri­al that showed lit­tle dif­fer­ence be­tween the drug and a place­bo.

That fail­ure in Oc­to­ber wiped 80% from Rel­ma­da’s stock price, and was fol­lowed by an­oth­er neg­a­tive read­out a few months lat­er. In both cas­es, the com­pa­ny said that there had been tri­al sites that were as­so­ci­at­ed with what it called sur­pris­ing place­bo ef­fects that skewed the re­sults com­pared with the drug, REL-1017.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.